Illnesses caused by many of the world's most deadly viruses cannot be effectively treated with existing drugs or vaccines. A study published by Cell Press in the March 21 issue of the journal Chemistry & Biology has revealed several compounds that can inhibit multiple viruses, such as highly lethal Ebola virus, as well as pathogens responsible for rabies, mumps, and measles, opening up new therapeutic avenues for combating highly pathogenic viruses.
"The medical field currently does not have ideal antiviral therapies, often no therapeutics at all, and the development of broad-spectrum antivirals is a great way to provide treatment in the future," says study author Claire Marie Filone of Boston University School of Medicine. "Toward that end, we have identified a drug that targets multiple viruses- and may be developed into an antiviral treatment for known and emerging viruses."
Many viruses that cause human diseases are nonsegmented, negative-strand (NNS) RNA viruses, which include the highly lethal Ebola virus and other pathogens mentioned above. In contrast to the many antibiotics that work against a wide range of bacteria, there are currently no highly effective or safe broad-spectrum drug treatments for viral diseases.
To address this need, John Connor and John Snyder of Boston University and their team screened thousands of diverse compounds for small molecules that showed strong antiviral activity against multiple NNS viruses. They identified several molecules that inhibited infection in cells exposed to either Ebola or another NNS virus called vesicular stomatitis virus. These molecules, which are related to a class of plant-derived compounds called indoline alkaloids, share a common chemical structure that can be modified to enhance antiviral activity.
The most potent of these compounds turned off NNS viral genes by blocking transcription. "Because our antiviral targets such a critical step in virus replication, we may be able to develop it into a therapeutic that could be used against many different types of viral infections," Filone says.
Materials provided by Cell Press. Note: Content may be edited for style and length.
Cite This Page: